Medetomidine/vatinoxan
 | |
 Chemical structures of medetomidine (top) and vatinoxan | |
| Combination of | |
|---|---|
| Medetomidine | alpha2-adrenoceptor agonist |
| Vatinoxan | alpha2-adrenoceptor antagonist |
| Clinical data | |
| Trade names | Zenalpha |
| License data | |
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status | |
Medetomidine/vatinoxan, sold under the brand name Zenalpha, is a veterinary fixed dose combination medication used as a sedative and analgesic for dogs.[1][2] It contains medetomidine, an alpha2-adrenoceptor agonist, as the hydrochloride; and vatinoxan, an alpha2-adrenoceptor antagonist, as the hydrochloride.[2][3]
It was approved for veterinary use in the United States in May 2022,[2] and in Canada in May 2023.[1]
References
- 1 2 3 "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-06-23]". Health Canada. 23 June 2023. Retrieved 3 March 2024.
- 1 2 3 4 "Zenalpha- vatinoxan hydrochloride and medetomidine hydrochloride solution". DailyMed. 11 May 2022. Retrieved 3 March 2024.
- ↑ "Zenalpha – Label" (PDF). Dechra Veterinary Products Inc. Government of Canada. 20 March 2023.
This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.